Gossamer Bio Provides Updated Seralutinib TORREY Open-Label Extension Data At The American Thoracic Society 2024 International Conference, Which Takes Place May 17-22
Author: Benzinga Newsdesk | May 14, 2024 04:15pm
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22in San Diego, California.
Posted In: GOSS